Medical News / ASH Meeting 2020: Measurable Residual Disease Could Improve Multiple Myeloma Treatment Decisions

A new study presented at the American Society of Hematology (ASH) 2020 Annual Meeting this weekend showed measurable residual disease (MRD) assessments may better inform therapy decision-making in patients with multiple myeloma. The retrospective trial, presented by an international team of US and Spain investigators, showed that therapy changes based on MRD resulted in prolonged progression-free survival in patients with multiple myeloma versus control. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

The modes of multiple myeloma assessment and screening has progressed over decades in near-alignment with the ... read more
A mobile health (mHealth) app may help children manage pain and symptoms related to sickle cell ... read more
Cognitive and emotional functions in pediatric patients should not be overlooked when assessing potential for sickle ... read more
There is a high false-negative rate of coronavirus disease 2019 (COVID-19) in patients with hematological malignancies, ... read more